Clinical Utility of a Pharmacostatistical Model for Ibandronate in Postmenopausal Osteoporosis

E-ISSN： 1875-5453|7|7|827-836

ISSN： 1389-2002

Source： Current Drug Metabolism, Vol.7, Iss.7, 2006-10, pp. : 827-836

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Ibandronate: A Review of its Use in the Management of Postmenopausal Osteoporosis

By Frampton James E. Perry Caroline M.

Drugs, Vol. 68, Iss. 18, 2008-01 ,pp. : 2683-2707

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Ibandronate for the Prevention of Fractures in Inflammatory Bowel Disease-Related Osteoporosis: Cost-Utility Analysis Using a Markov Model

By Kreck Simon Klaus Jochen

PharmacoEconomics, Vol. 26, Iss. 4, 2008-01 ,pp. : 311-328

Adis International

Access to resources Recommend Favorite

Oral ibandronate: a less frequently administered therapeutic option for postmenopausal osteoporosis

By Reginster Jean-Yves

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 13, 2005-10 ,pp. : 2301-2313

Informa Healthcare

Access to resources Recommend Favorite

Oral and Intravenous Ibandronate in the Management of Postmenopausal Osteoporosis: A Comprehensive Review

Current Pharmaceutical Design, Vol. 11, Iss. 28, 2005-11 ,pp. : 3711-3728

Bentham Science Publishers

Access to resources Recommend Favorite

Intravenous Ibandronate: In the Treatment of Osteoporosis

By Croom Katherine F. Scott Lesley J.

Drugs, Vol. 66, Iss. 12, 2006-01 ,pp. : 1593-1601

Adis International

Access to resources Recommend Favorite